Tonix Pharmaceuticals Holding (TNXP) EBIT Margin (2023 - 2025)
Historic EBIT Margin for Tonix Pharmaceuticals Holding (TNXP) over the last 3 years, with Q3 2025 value amounting to 1005.08%.
- Tonix Pharmaceuticals Holding's EBIT Margin fell 4539100.0% to 1005.08% in Q3 2025 from the same period last year, while for Sep 2025 it was 969.97%, marking a year-over-year increase of 2836900.0%. This contributed to the annual value of 1354.28% for FY2024, which is 1696600.0% up from last year.
- As of Q3 2025, Tonix Pharmaceuticals Holding's EBIT Margin stood at 1005.08%, which was down 4539100.0% from 1416.22% recorded in Q2 2025.
- In the past 5 years, Tonix Pharmaceuticals Holding's EBIT Margin ranged from a high of 551.17% in Q3 2024 and a low of 3501.63% during Q2 2024
- Moreover, its 3-year median value for EBIT Margin was 860.23% (2024), whereas its average is 1143.86%.
- Over the last 5 years, Tonix Pharmaceuticals Holding's EBIT Margin had its largest YoY gain of 20854100bps in 2025, and its largest YoY loss of -4539100bps in 2025.
- Over the past 3 years, Tonix Pharmaceuticals Holding's EBIT Margin (Quarter) stood at 723.18% in 2023, then dropped by -20bps to 870.64% in 2024, then fell by -15bps to 1005.08% in 2025.
- Its EBIT Margin was 1005.08% in Q3 2025, compared to 1416.22% in Q2 2025 and 660.93% in Q1 2025.